Clinomics Balance Sheet Health
Financial Health criteria checks 2/6
Clinomics has a total shareholder equity of ₩44.6B and total debt of ₩32.8B, which brings its debt-to-equity ratio to 73.6%. Its total assets and total liabilities are ₩105.7B and ₩61.1B respectively.
Key information
73.6%
Debt to equity ratio
₩32.81b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩6.63b |
| Equity | ₩44.57b |
| Total liabilities | ₩61.13b |
| Total assets | ₩105.70b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A352770's short term assets (₩21.1B) do not cover its short term liabilities (₩51.1B).
Long Term Liabilities: A352770's short term assets (₩21.1B) exceed its long term liabilities (₩10.0B).
Debt to Equity History and Analysis
Debt Level: A352770's net debt to equity ratio (58.7%) is considered high.
Reducing Debt: A352770's debt to equity ratio has reduced from 214.8% to 73.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A352770 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A352770 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.6% each year